Cytek Biosciences (CTKB) Net Cash Flow Growth (1y) (2021 - 2026)
Cytek Biosciences (CTKB) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -54.17% |
| 10 | Cytek Biosciences | 602.64 Mn | 528.79 Mn | 28.34 Mn | 140.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.06% |
| Mar 31, 2026 | -1,064.74% |
| Dec 31, 2025 | 94.10% |
| Sep 30, 2025 | 215.61% |
| Jun 30, 2025 | -390.21% |
| Mar 31, 2025 | -1,105.43% |
| Dec 31, 2024 | -1,449.00% |
| Sep 30, 2024 | -147.93% |
| Jun 30, 2024 | 4,076.28% |
| Mar 31, 2024 | 99.89% |
| Dec 31, 2023 | 111.76% |
| Sep 30, 2023 | 460.17% |
| Jun 30, 2023 | 101.39% |
| Mar 31, 2023 | -8,656.12% |
| Dec 31, 2022 | -219.70% |
| Sep 30, 2022 | -103.92% |
| Jun 30, 2022 | -26.14% |
| Mar 31, 2022 | -195.56% |
| Dec 31, 2021 | -109.78% |
| Sep 30, 2021 | 43,113.35% |